EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

Adam Irving iD, Dennis Petrie, Anthony Harris, Laura Fanning, Erica M Wood, Elizabeth Moore, Cameron Wellard, Neil Waters, Kim Huynh, Bradley Augustson, Gordon Cook, Francesca Gay und 4 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0308812 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Adam Irving und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Economics, Monash Business School, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Multiple Myeloma, Registries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem cell transplantation and has been rapidly evolving in recent years. However, clinical trials are unable to provide patients and clinicians with long-term prognostic information nor policymakers with the full body of evidence needed to perform economic evaluation of new therapies or make reimbursement decisions. To address these limitations of the available evidence, this study aimed to develop and validate the EpiMAP Myeloma model, a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways. Risk equations were estimated using the Australian and New Zealand Myeloma & Related Diseases Registry after multiple imputation of missing data. Risk equation coefficients were combined with multiple myeloma patients at diagnosis from the Registry to perform the simulation. The model was validated with 100 bootstraps of an out-of-sample prediction analysis using a 70/30 split of the 4,121 registry patients diagnosed between 2009 and 2023, resulting in 2,884 and 1,237 patients in the training and validation cohorts, respectively. For 90% of the 120 months in the 10-year post-diagnosis period, there was no significant difference in overall survival between the validation and simulated cohorts. These results highlight that the EpiMAP Myeloma model is robust at predicting multiple myeloma disease outcomes and treatment pathways in Australia & New Zealand. In the future, clinicians will be able to use the EpiMAP Myeloma model to provide personalised estimates of life expectancy to patients based on their specific characteristics, disease stage, and response to treatment. Policymakers will also be able to use the model to perform economic evaluation, to forecast the number of patients receiving treatment at different stages, and to determine the downstream impact of listing new, effective therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaRegistriesHumansMaleAustraliaFemaleAgedMiddle AgedNew ZealandTreatment OutcomeComputer SimulationPrognosisAged, 80 and overAdult

Autor:innen und Institutionen

  • Centre for Health Economics, Monash Business School, Monash University, Melbourne, Victoria, Australia.
  • Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Turino, Torino, Italy.
  • Department of Haematology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Adam Irving

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Irving, A., Petrie, D., Harris, A., Fanning, L., Wood, E. M., Moore, E., Wellard, C., Waters, N., Huynh, K., Augustson, B., Cook, G., Gay, F., McCaughan, G., Mollee, P., Spencer, A., & McQuilten, Z. K. (2024). Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLOS ONE. https://doi.org/10.1371/journal.pone.0308812

Vancouver

Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, et al. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLOS ONE. 2024. doi:10.1371/journal.pone.0308812

BibTeX
@article{Irving2024,
  author = {Irving, Adam and Petrie, Dennis and Harris, Anthony and Fanning, Laura and Wood, Erica M and Moore, Elizabeth and Wellard, Cameron and Waters, Neil and Huynh, Kim and Augustson, Bradley and Cook, Gordon and Gay, Francesca and McCaughan, Georgia and Mollee, Peter and Spencer, Andrew and McQuilten, Zoe K},
  title = {Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0308812}
}
Kostenlos starten →